FDA clears Vitestro's Aletta robotic blood draw device via De Novo
The US Food and Drug Administration has granted marketing authorisation to Vitestro for the Aletta, a standalone robotic device capable of drawing blood from a patient's arm without direct hands-on operator intervention. The clearance, granted through the De Novo regulatory pathway for novel low- to moderate-risk devices, marks the first time the FDA has authorised a fully autonomous blood draw system for outpatient use in adults.
The Aletta is designed to let a single trained phlebotomist oversee up to three devices simultaneously, a ratio the FDA says could help ease a documented shortage of qualified phlebotomy staff in the United States. The supervising phlebotomist initiates each session and remains on hand to respond to issues, but the device independently handles every subsequent step.
How the device works
Once the patient positions their arm and a button is pressed to begin the procedure, the Aletta uses near-infrared light and Doppler ultrasound to identify a suitable vein and distinguish it from surrounding arteries. If no acceptable vein is detected, the device will not proceed. Where a vein is confirmed, the system applies a tourniquet, disinfects the skin, inserts the needle, manages collection tube sequencing, disposes of the needle and applies a bandage. The supervising phlebotomist verifies tube fill levels after the draw is complete.
Safety architecture is layered throughout. The device continuously applies disinfectant during the ultrasound scan, is cleaned between patients by a trained professional, and includes sensors that pause the procedure and alert the supervisor if unsafe conditions are detected. If the patient moves excessively during the draw, the needle detaches automatically and the procedure stops.
Michelle Tarver, Director of the FDA's Centre for Devices and Radiological Health, said blood draws are among the most commonly performed medical procedures in the country, yet patients increasingly face delays because of a growing shortage of trained phlebotomists.
Clinical data submitted to support the De Novo application showed that the Aletta achieves successful blood draw rates comparable to, or better than, those of trained human phlebotomists when it proceeds to a stick. Performance was demonstrated across a broad patient population, including individuals who self-reported difficult vein access and those with varying skin tones. Device-related adverse events were described as uncommon and mild.
Market context and regulatory read-across
The De Novo authorisation simultaneously establishes special controls for the new device type, covering labelling, performance testing and clinical testing requirements. Future applicants seeking to market substantially equivalent products will reference those controls via the 510(k) pathway, meaning the Aletta decision effectively creates a new regulatory category for autonomous phlebotomy devices.
The broader medical robotics sector has seen sustained investment over the past several years, with robotic surgical platforms and autonomous laboratory instruments attracting significant venture and strategic interest. Autonomous specimen collection sits at the intersection of medical devices, diagnostics workflow and labour economics, a combination that is likely to draw interest from diagnostics groups and hospital networks seeking to manage staffing costs without compromising throughput.
The authorisation is currently limited to outpatient settings in adults. Extensions to inpatient environments or paediatric populations would require further clinical data and separate regulatory submissions, representing a natural pipeline for Vitestro as it seeks to broaden the commercial footprint of the platform.